Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oxford BioMedica plc (GB:OXB)
LSE:OXB
Holding GB:OXB?
Track your performance easily
OXB Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range164.29p - 394.50p
Previous Close341p
Volume806.00
Average Volume (3M)128.83K
Market Cap
£359.21M
Enterprise Value363.75M
Total Cash (Recent Filing)£141.28M
Total Debt (Recent Filing)£114.28M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Sep 23, 2024EPS Estimate
-£0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding105,341,569
10 Day Avg. Volume99,581
30 Day Avg. Volume128,828
Standard Deviation0.16
R-Squared0.13
Alpha-0.00319
Financial Highlights & Ratios
Price to Book (P/B)209.20
Price to Sales (P/S)3.12
Price to Cash Flow (P/CF)-33.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
401.73pPrice Target Upside18.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Oxford BioMedica News
PremiumCompany Announcements
Oxford Biomedica Emerges as OXB with Global Vision
PremiumCompany Announcements
Oxford Biomedica Announces Voting Rights Total
PremiumCompany Announcements
Oxford Biomedica Welcomes New CFO Lucinda Crabtree
PremiumCompany Announcements
Oxford Biomedica Enhances Board, Fuels InnovationOptions Prices
Currently, No data available
---
Ownership Overview
61.96% Insiders
6.46% Mutual Funds
2.26% Other Institutional Investors
29.33% Public Companies and
Individual Investors
OXB FAQ
What was Oxford BioMedica plc’s price range in the past 12 months?
Oxford BioMedica plc lowest share price was 164.29p and its highest was 394.50p in the past 12 months.
What is Oxford BioMedica plc’s market cap?
Currently, no data Available
When is Oxford BioMedica plc’s upcoming earnings report date?
Oxford BioMedica plc’s upcoming earnings report date is Sep 23, 2024 which is in 3 days.
How were Oxford BioMedica plc’s earnings last quarter?
Oxford BioMedica plc released its earnings results on Apr 29, 2024. The company reported -1.134p earnings per share for the quarter, missing the consensus estimate of -0.492p by -0.642p.
Is Oxford BioMedica plc overvalued?
According to Wall Street analysts Oxford BioMedica plc’s price is currently Undervalued.
Does Oxford BioMedica plc pay dividends?
Oxford BioMedica plc does not currently pay dividends.
What is Oxford BioMedica plc’s EPS estimate?
Oxford BioMedica plc’s EPS estimate is -£0.28.
How many shares outstanding does Oxford BioMedica plc have?
Oxford BioMedica plc has 105,341,570 shares outstanding.
What happened to Oxford BioMedica plc’s price movement after its last earnings report?
Oxford BioMedica plc reported an EPS of -1.134p in its last earnings report, missing expectations of -0.492p. Following the earnings report the stock price went up 13.786%.
Which hedge fund is a major shareholder of Oxford BioMedica plc?
Currently, no hedge funds are holding shares in GB:OXB
---
Oxford BioMedica Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
401.73p (18.50% Upside)
401.73p (18.50% Upside)
Insider Transactions
Sold Shares
Worth $7.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.95%
12-Months-Change
Fundamentals
Return on Equity
-115.34%
Trailing 12-Months
Asset Growth
-41.89%
Trailing 12-Months
Company Description
Oxford BioMedica plc
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the Platform and Product segment. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1996 and is headquartered in Oxford, the United Kingdom.
---
OXB Company Deck
---
OXB Earnings Call
Q4 2024
0:00 / 0:00
---
OXB Stock 12 Month Forecast
Average Price Target
401.73p
▲(18.50% Upside)
Technical Analysis
Oxford BioMedica
―
Advaxis
―
TRACON Pharmaceuticals
―
Cyclacel Pharmaceuticals
―
Armata Pharmaceuticals
―
Best Analysts Covering OXB
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
-2.20%
reiterated a buy rating 4 months ago
Copying Charles Weston's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of -2.20% per trade.
---